In addition, IAG933, a selective small-molecule inhibitor disrupting YAP/TAZ-TEAD protein-protein interactions, is being evaluated in a Phase I trial (NCT04857372) involving malignant mesothelioma and other tumors with NF2/LATS1/2 mutations or YAP/TAZ fusions (118). The gene discussed is YAP1; the disease is malignant mesothelioma.